Arch Biopartners Inc. (ACHFF)
USD 1.27
(0.79%)
USD 1.27
(0.79%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -2.97 Million CAD | -385.54% |
| 2022 | -1.08 Million CAD | -21.14% |
| 2021 | -891.53 Thousand CAD | 80.0% |
| 2020 | - CAD | -97.99% |
| 2019 | - CAD | 28.92% |
| 2018 | - CAD | -68.45% |
| 2017 | - CAD | -91.8% |
| 2016 | - CAD | -10.32% |
| 2015 | -820.93 Thousand CAD | -176.9% |
| 2014 | -320.99 Thousand CAD | -86.34% |
| 2013 | -172.26 Thousand CAD | 45.23% |
| 2012 | -314.51 Thousand CAD | 23.66% |
| 2011 | -411.98 Thousand CAD | -203.07% |
| 2010 | -135.93 Thousand CAD | 25.22% |
| 2009 | -181.79 Thousand CAD | 60.16% |
| 2008 | -456.3 Thousand CAD | -142.47% |
| 2007 | -188.19 Thousand CAD | -272.18% |
| 2006 | 109.29 Thousand CAD | 135.91% |
| 2005 | -304.39 Thousand CAD | 70.14% |
| 2004 | -1.02 Million CAD | -156.23% |
| 2003 | -430.09 Thousand CAD | -87.91% |
| 2002 | -505.00 CAD | -126.55% |
| 2001 | 797.52 Thousand CAD | 190.49% |
| 2000 | -881.34 Thousand CAD | -24.57% |
| 1999 | -707.5 Thousand CAD | -51.64% |
| 1998 | -466.55 Thousand CAD | 58.81% |
| 1997 | -1.13 Million CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -1 Million CAD | 0.0% |
| 2024 Q2 | -1.05 Million CAD | 0.0% |
| 2024 Q3 | -767.65 Thousand CAD | 100.0% |
| 2023 Q2 | -896.03 Thousand CAD | 58.18% |
| 2023 Q3 | -474.3 Thousand CAD | 47.07% |
| 2023 Q4 | 533.41 Thousand CAD | 212.46% |
| 2023 FY | - CAD | -385.54% |
| 2023 Q1 | -2.14 Million CAD | -509.19% |
| 2022 Q4 | -351.74 Thousand CAD | -78.6% |
| 2022 Q3 | -196.94 Thousand CAD | 53.38% |
| 2022 Q2 | -422.43 Thousand CAD | -287.86% |
| 2022 Q1 | -108.91 Thousand CAD | -114.46% |
| 2022 FY | - CAD | -21.14% |
| 2021 Q1 | -1.6 Million CAD | -2.82% |
| 2021 Q4 | 753.42 Thousand CAD | -22.53% |
| 2021 FY | - CAD | 80.0% |
| 2021 Q3 | 972.51 Thousand CAD | 195.98% |
| 2021 Q2 | -1.01 Million CAD | 37.03% |
| 2020 Q1 | -697.02 Thousand CAD | 25.49% |
| 2020 Q2 | -49.75 Thousand CAD | 92.86% |
| 2020 Q3 | -2.14 Million CAD | -4213.75% |
| 2020 Q4 | -1.56 Million CAD | 27.08% |
| 2020 FY | - CAD | -97.99% |
| 2019 Q1 | -814.23 Thousand CAD | -7.57% |
| 2019 FY | - CAD | 28.92% |
| 2019 Q4 | -935.51 Thousand CAD | -4753.51% |
| 2019 Q2 | -482.71 Thousand CAD | 40.72% |
| 2019 Q3 | -19.27 Thousand CAD | 96.01% |
| 2018 Q2 | -599.65 Thousand CAD | -81.37% |
| 2018 Q3 | -1.48 Million CAD | -146.96% |
| 2018 Q1 | -330.61 Thousand CAD | -54.59% |
| 2018 FY | - CAD | -68.45% |
| 2018 Q4 | -756.91 Thousand CAD | 48.89% |
| 2017 Q1 | -230.16 Thousand CAD | 32.14% |
| 2017 Q2 | -148.05 Thousand CAD | 35.67% |
| 2017 Q4 | -213.87 Thousand CAD | 83.56% |
| 2017 FY | - CAD | -91.8% |
| 2017 Q3 | -1.3 Million CAD | -778.39% |
| 2016 FY | - CAD | -10.32% |
| 2016 Q2 | -303.11 Thousand CAD | -88.58% |
| 2016 Q3 | -177.54 Thousand CAD | 41.43% |
| 2016 Q4 | -339.17 Thousand CAD | -91.03% |
| 2016 Q1 | -160.73 Thousand CAD | 12.55% |
| 2015 FY | - CAD | -176.9% |
| 2015 Q1 | -363.38 Thousand CAD | -278.36% |
| 2015 Q4 | -183.8 Thousand CAD | -19.61% |
| 2015 Q3 | -153.66 Thousand CAD | 18.25% |
| 2015 Q2 | -187.97 Thousand CAD | 48.27% |
| 2014 Q1 | -49.43 Thousand CAD | 6.09% |
| 2014 FY | - CAD | -86.34% |
| 2014 Q2 | -53.84 Thousand CAD | -8.93% |
| 2014 Q4 | -96.04 Thousand CAD | 21.07% |
| 2014 Q3 | -121.67 Thousand CAD | -125.98% |
| 2013 Q1 | -29.09 Thousand CAD | 67.67% |
| 2013 FY | - CAD | 45.23% |
| 2013 Q4 | -52.63 Thousand CAD | -274.79% |
| 2013 Q2 | -76.49 Thousand CAD | -162.9% |
| 2013 Q3 | -14.04 Thousand CAD | 81.64% |
| 2012 Q4 | -89.98 Thousand CAD | -5.63% |
| 2012 Q3 | -85.18 Thousand CAD | -50.26% |
| 2012 FY | - CAD | 23.66% |
| 2012 Q1 | -87.57 Thousand CAD | -22.16% |
| 2012 Q2 | -56.68 Thousand CAD | 35.27% |
| 2011 Q1 | -103.78 Thousand CAD | -101.48% |
| 2011 Q3 | -159.26 Thousand CAD | -106.21% |
| 2011 FY | - CAD | -203.07% |
| 2011 Q4 | -71.69 Thousand CAD | 54.99% |
| 2011 Q2 | -77.23 Thousand CAD | 25.58% |
| 2010 Q4 | 6.99 Million CAD | 24718.43% |
| 2010 Q1 | -98.57 Thousand CAD | -268.27% |
| 2010 Q3 | -28.41 Thousand CAD | -18.19% |
| 2010 FY | - CAD | 25.22% |
| 2010 Q2 | -24.03 Thousand CAD | 75.61% |
| 2009 Q1 | -413.6 Thousand CAD | -496.25% |
| 2009 Q2 | -57.5 Thousand CAD | 86.1% |
| 2009 Q3 | 4.71 Million CAD | 8305.25% |
| 2009 FY | - CAD | 60.16% |
| 2009 Q4 | -26.76 Thousand CAD | -100.57% |
| 2008 Q3 | -54.21 Thousand CAD | 41.62% |
| 2008 Q1 | -154.94 Thousand CAD | -4592.46% |
| 2008 FY | - CAD | -142.47% |
| 2008 Q4 | 104.37 Thousand CAD | 292.54% |
| 2008 Q2 | -92.86 Thousand CAD | 40.06% |
| 2007 FY | - CAD | -272.18% |
| 2007 Q3 | 2449.00 CAD | 107.56% |
| 2007 Q4 | -3302.00 CAD | -234.83% |
| 2007 Q2 | -32.39 Thousand CAD | -112.81% |
| 2007 Q1 | 252.94 Thousand CAD | 720.16% |
| 2006 Q1 | -216.63 Thousand CAD | -225.8% |
| 2006 Q2 | -79.55 Thousand CAD | 63.27% |
| 2006 Q3 | -12.33 Thousand CAD | 84.5% |
| 2006 Q4 | -40.78 Thousand CAD | -230.71% |
| 2006 FY | - CAD | 135.91% |
| 2005 FY | - CAD | 70.14% |
| 2005 Q4 | 172.2 Thousand CAD | 258.1% |
| 2005 Q3 | -108.92 Thousand CAD | 27.89% |
| 2005 Q2 | -151.04 Thousand CAD | 77.17% |
| 2005 Q1 | -661.6 Thousand CAD | -98.33% |
| 2004 Q1 | -219.16 Thousand CAD | -130.59% |
| 2004 Q4 | -333.58 Thousand CAD | -628.7% |
| 2004 Q3 | 63.09 Thousand CAD | 174.07% |
| 2004 FY | - CAD | -156.23% |
| 2004 Q2 | -85.18 Thousand CAD | 61.13% |
| 2003 Q1 | -47.98 Thousand CAD | -227.47% |
| 2003 FY | - CAD | -87.91% |
| 2003 Q3 | -11.79 Thousand CAD | 83.59% |
| 2003 Q2 | -71.86 Thousand CAD | -49.77% |
| 2003 Q4 | -95.04 Thousand CAD | -705.94% |
| 2002 Q1 | 887.94 Thousand CAD | 1651.34% |
| 2002 FY | - CAD | -126.55% |
| 2002 Q3 | -80.63 Thousand CAD | -24.41% |
| 2002 Q4 | -14.65 Thousand CAD | 81.83% |
| 2002 Q2 | -64.81 Thousand CAD | -107.3% |
| 2001 FY | - CAD | 190.49% |
| 2001 Q3 | -24.06 Thousand CAD | -158.86% |
| 2001 Q2 | -9297.00 CAD | 97.26% |
| 2001 Q1 | -338.79 Thousand CAD | -56.98% |
| 2001 Q4 | -57.23 Thousand CAD | -137.83% |
| 2000 FY | - CAD | -24.57% |
| 2000 Q3 | -283.84 Thousand CAD | -561.96% |
| 2000 Q4 | -215.81 Thousand CAD | 23.97% |
| 2000 Q2 | -42.88 Thousand CAD | 90.06% |
| 2000 Q1 | -431.47 Thousand CAD | -371.16% |
| 1999 Q2 | -65.74 Thousand CAD | 73.09% |
| 1999 Q1 | -244.28 Thousand CAD | -370.39% |
| 1999 FY | - CAD | -51.64% |
| 1999 Q3 | -118.7 Thousand CAD | -80.56% |
| 1999 Q4 | -91.57 Thousand CAD | 22.85% |
| 1998 Q2 | -116.96 Thousand CAD | 0.0% |
| 1998 Q4 | -51.93 Thousand CAD | 58.75% |
| 1998 FY | - CAD | 58.81% |
| 1998 Q3 | -125.88 Thousand CAD | -7.63% |
| 1997 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -3.06 Million USD | 2.72% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 15.994% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -30.431% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 82.846% |
| GB Sciences, Inc. | -1.41 Million USD | -109.854% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 886.522% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -24265.778% |
| Skye Bioscience, Inc. | -13.54 Million USD | 78.006% |
| Zenith Capital Corp. | -8.6 Million USD | 65.377% |
| Agentix Corp. | -1.37 Million USD | -117.217% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 23.289% |
| Biomind Labs Inc. | -1.03 Million USD | -188.018% |
| ContraFect Corporation | -64.99 Million USD | 95.416% |
| CSL Limited | 4.78 Billion USD | 100.062% |
| CytoDyn Inc. | -18.02 Million USD | 83.473% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 44414.262% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -371.167% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 94.616% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -711.416% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -93.984% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -218.021% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 103.169% |
| SQZ Biotechnologies Company | -64.14 Million USD | 95.354% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -100.327% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 95.805% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -12.677% |
| Mesoblast Limited | -62.38 Million USD | 95.224% |
| Marizyme, Inc. | -34.28 Million USD | 91.308% |
| Genus plc | 73.7 Million USD | 104.043% |
| Pharming Group N.V. | 9.87 Million USD | 130.168% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 66.032% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -112.561% |
| IMV Inc. | -35.52 Million USD | 91.612% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -28.224% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -475.179% |
| ONE Bio Corp. | 13.61 Million USD | 121.888% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 93.822% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 183.418% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -3.021% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 58.392% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -11818.764% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 81.224% |
| Alpha Cognition Inc. | -9.7 Million USD | 69.299% |
| Enzolytics Inc. | -2.12 Million USD | -40.417% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -216.02 Million USD | 98.621% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 344.839% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 133.654% |
| Genscript Biotech Corporation | -248.71 Million USD | 98.802% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 49.743% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -1145.951% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -21.796% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -1592.772% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -55.119% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 54.932% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 34.168% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | 20.466% |
| Helix BioMedix, Inc. | -1.04 Million USD | -184.78% |
| EV Biologics, Inc. | -1.26 Million USD | -135.152% |
| Q BioMed Inc. | -617.62 Thousand USD | -382.441% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -70.268% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 92.483% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.55 Million USD | 60.553% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -19.094% |
| HST Global, Inc. | -5303.00 USD | -56088.78% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -44.856% |
| Halberd Corporation | -74.27 Thousand USD | -3911.485% |
| Resverlogix Corp. | -11.74 Million USD | 74.624% |
| Cell Source, Inc. | -4.27 Million USD | 30.259% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -98.791% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | -6.11 Million USD | 51.254% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -17004.018% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -1.03 Million USD | -187.949% |
| Kadimastem Ltd | -2.62 Million USD | -13.539% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -684.914% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -1545.438% |
| LadRx Corporation | 412.28 Thousand USD | 822.73% |
| Regen BioPharma, Inc. | 1.46 Million USD | 303.259% |
| Affymax, Inc. | -14.29 Million USD | 79.156% |
| Itoco Inc. | -1.86 Million USD | -59.427% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -166.997% |
| Mobile Lads Corp. | -2.24 Million USD | -32.953% |
| International Stem Cell Corporation | 202 Thousand USD | 1575.095% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | -3.82 Million USD | 22.001% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -3670.377% |
| Qrons Inc. | -40.08 Thousand USD | -7334.173% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -513.512% |
| SYBLEU INC | -141.57 Thousand USD | -2004.733% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 664.942% |
| Rebus Holdings, Inc. | -951 Thousand USD | -213.322% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -180.571% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -5560.507% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -21.031% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 91.693% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -6521.536% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -8.827% |
| Neutra Corp. | -181.24 Thousand USD | -1543.995% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 85.219% |
| PureTech Health plc | -11.62 Million USD | 74.373% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 85.218% |
| IXICO plc | -707 Thousand USD | -321.456% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 61.227% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 93.837% |
| CSL Limited | 4.73 Billion USD | 100.063% |
| Cellectis S.A. | -92.63 Million USD | 96.783% |